MTC patients follow-up is performed by assessment of serum Ctn and carcinoembryonic antigen (CEA) along with imaging evaluations [9], however MTC progression is not always accompanied by the increase of these serum biomarkers leading to MTC patients’ progression remaining undetected until the presence of a new lesion. Here, CEACAM5 is linked to medullary thyroid gland carcinoma.